Cardiovascular effects of oral hypoglycaemic drugs

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 3, 1996, Pages 201-206

  Howes, Laurence Guy ^a   Sundaresan, Purnima ^a   Lykos, Denise ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

arrhythmia; biguanides; diazoxide; glibenclamide; hypertension; hypoglycaem ia; metformin; non insulin dependent diabetes mellitus; sulfonylureas; tolbutamide

Indexed keywords

ACETOHEXAMIDE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DIAZOXIDE; GLIBENCLAMIDE; GLIPIZIDE; METFORMIN; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

HEART ARRHYTHMIA; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 0029888911     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02596.x     Document Type: Review

References (54)

1. Weideman P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care 1991; 14: 220-32.
2. Vitsitupa M, Niskanan L, Siitonen O, Voutilainen E, Pyrola K. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. Circulation 1990; 82: 27-36.
3. Morris AD, Connell JM. Insulin resistance and essential hypertension: Mechanisms and clinical implications. Am. J. Med. Sci. 1994; 307 (Suppl. 1): S47-52.
4. + channel activators, RP 52891, cromakalim and diazoxide, on the plasma renin activity and blood pressure in rats. J. Pharmacol. Exp. Ther. 1991; 258: 216-22.
5. Wales JK, Grant AM, Wolff FW. The effect of tolbutamide on blood pressure. J. Pharmacol. Exp. Ther. 1971; 178: 130-40.
6. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. Diabetes 1970; 19 (Suppl. 2): 747-830.
7. Bonora E, Moghetti P, Querena M et al. Studies on the mechanism of action of sulfonylureas in type II diabetic subjects: Gliquidone. J. Endocrinol. Invest. 1992; 15: 1-11.
8. Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DR. Insulin, glibenclamide or metformin treatment for non insulin dependant diabetes: Heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes Res. 1992; 19: 69-76.
9. Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet. Med. 1990; 7: 510-14.
10. Ballagi-Pordany G, Koltai MZ, Aranyi Z, Pogatsa G. Direct effect of hypoglycemic sulphonylureas on the cardiovascular system of dogs. Diabetes Res. Clin. Pract. 1991; 11: 47-52.
11. Lasseter KC, Levey GS, Palmer RF, McCarthy JS. The effect of sulfonylurea drugs on rabbit myocardial contractility, canine purkinje fiber automaticity, and adenyl cyclase activity from rabbit and human hearts. J. Clin. Invest. 1972; 51: 2429-34.
12. Levey GS, Lasseter KC, Palmer RF. Sulfonylureas and the heart. Ann. Rev. Med. 1974; 25: 69-74.
13. Young JL, Burr IM, Perry JM, Nelson JH, Nies AS. Inotropic effects of tolbutamide in man. Am. Heart J. 1975; 89: 189-94.
14. Tosaki A, Szerdahelyi P, Engelman RM, Das DK. Potassium channel openers and blockers: Do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts. J. Pharmacol. Exp. Ther. 1993; 267: 1355-62.
15. Black SC, Fagbemi SO, Chi L, Friedrichs GS, Lucchesi BR. Phorbol ester-induced ventricular fibrillation in the Langendorff-perfused rabbit heart: Antagonism by staurosporine and glibenclamide. J. Mol. Cell Cardiol. 1993; 25: 1427-38.
16. Tweedie D, Henderson C, Kane K. Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur. J. Pharmacol. 1993; 240: 251-7.
17. Cacciapuoti F, Spiezia R, Bianchi U, Lama D, D'Avino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischaemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am. J. Cardiol. 1991; 67: 843-7.
18. Hofmann D, Opie L. Potassium channel blockade and acute myocardial infarction: Implications for management of the non-insulin requiring diabetic patient. Eur. Heart J. 14: 1585-9.
19. + opener aprikalim (RP52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J. Pharmacol. Exp. Ther. 1991; 259: 961-7.
20. Auchampach J, Maruyama M, Cavero I, Gross G. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 1992; 86: 311-19.
21. Grover G, McCullough J, Henry D, Conder M, Sleph P. Antiischaemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. J. Pharmacol. Exp. Ther. 1989; 251: 98-104.
22. Steinberg MI, Wiest SA, Zimmerman KM, Ertel PJ, Bemis KG, Robertson DW. Chiral recognition of pinacidil and its 3-pyridyl isomer by canine cardiac and smooth muscle: Antagonism by sulfonylureas. J. Pharmacol. Exp. Ther. 1991; 256: 222-9.
23. Soares de Moura R, Jasbik W. Actions of cromakalim in isolated human saphenous vein. Hypertension 1992; 19 (Suppl. 2): 121-4.
24. American Hospital Formulatory Service. Drug Information Service. American Society of Hospital Pharmacy Inc., Bethesda. 1992; 1998-9.
25. Bijlstra PJ, Smits P, Lutterman JA, Thein T. Glibenclamide inhibits the vasodilator effect of diazoxide in man. J. Hypertens. 1994; 12 (Suppl. 3): S104.
26. Atp channels. Clin. Exp. Pharmacol. Physiol. 1994; 21: 583-97.
27. Baron AD. Haemodynamic actions of insulin. Am. J. Physiol. 1994; 262: E187-202.
28. Chan JCN, Tomlinson B, Critchley JAJH, Cockram CS, Walden RJ. Metabolic and haemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993; 16: 1035-8.
29. Schmidtt J, Moore J. Hypertension secondary to chlorpropamide with amelioration by changing to insulin. Am. J. Hypertens. 1993; 6: 317-19.
30. Carlson L, Ostman J. Effect of chlorpropamide treatment on serum lipid levels in diabetes mellitus. Acta Med. Scand. 1961; 170: 561-4.
31. Morris J, West D, Bolinger R. Effect of oral sulfonylurea on plasma triglycerides in diabetics. Diabetes 1964; 13: 87-9.
32. Paisey R, Elkeles R, Hambley J, Magill P. The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal. Diabetologia 1978; 16: 81-5.
33. Simpson R, Mann J, Hockaday T, Hockaday J, Turner R, Jeffs R. Lipid abnormalities in untreated maturity-onset diabetics and the effect of treatment. Diabetologia 1979; 16: 101-6.
34. Greenfield M, Doberne L, Rosenthal M, Vreman H, Reaven G. Lipid metabolism in non-insulin-dependent diabetes mellitus. Effect of glipizide therapy. Arch. Intern. Med. 1982; 142: 1498-1500.
35. Pfeifer M, Brunzell J, Best J, Judzewitsh R, Halter J, Porte D. The response of plasma triglyceride, cholesterol, and lipoprotein lipase to treatment in non-insulin-dependent diabetic subjects without familial hypertriglyceridemia. Diabetes 1983; 32: 525-31.
36. Howard B, Xiaoren P, Harper I, Foley J, Cheung M, Taskinen M. Effect of sulphonylurea therapy on plasma lipids and high density lipoprotein composition in non-insulin-dependent diabetes mellitus. Am. J. Med. 1985; 79 (Suppl. 3B): 78-85.
37. Rains SGH, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet. Med. 1988; 5: 653-8.
38. Chen K, Juang J, Huang H, Lin J, Huang B, Huang M. Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus. Chang-Keng-T-Hsueh 1993; 16: 246-50.
39. Ishizuka T, Taniguchi O, Yamamoto M et al. Thrombin-induced platelet aggregation, phosphoinositide metabolism and protein phosphorylation in NIDDM patients treated by diet, sulfonylurea or insulin. Diabetologia 1994; 37: 632-8.
40. Ozaki Y, Yatomi Y, Kume S. Effects of oral hypoglycaemic agents on platelet functions. Biochem. Pharmacol. 1992; 44: 687-91.
41. Satoh K, Ozaki Y, Yatomi Y, Kume S. Effects of sulfonylurea agents on platelet homogenates. Biochem Pharmacol. 1994; 48: 1053-5.
42. Bradley FR, Dolger H, Forsham PH, Seltzer H. Settling the UGDP controversy. JAMA 1975; 232: 813-17.
43. Giugliano D, De Rosa N, Di Maro G et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387-90.
44. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J. Intern. Med. 1991; 229: 181-7.
45. Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J. Intern. Med. 1994; 235: 335-41.
46. Gerich J. Oral hypoglycemic agents. N. Engl. J. Med. 1989; 321: 1231-45.
47. Nosadini R, Avogaro A, Trevisan R et al. Effects of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10: 62-7.
48. Montanari G, Bondioli A, Rizzato G et al. Treatment with low dose metformin in patients with peripheral vascular disease. Pharmacol. Res. 1992; 25: 63-73.
49. Rains SGH, Wilson GA, Richmond W, Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. J. R. Soc. Med 1989; 82: 93-4.
50. Leung WH, Lau CP, Wong CK. Beneficial effects of cholesterol lowering therapy on coronary endothelium dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-1500.
51. Straznicky NE, Howes LG, Lam W, Louis WJ. Provastatin reduces cardiovascular reactivity to noradrenaline and angiotensin II in hypercholesterolemic hypertensives. Am. J. Cardiol. 1995; 75: 582-6.
52. Cho YW, Yang DH, Oh DY et al. Plasma, t-PA and PA1-1 antigen concentations in non-insulin dependent diabetic patients: Effects of treatment modality on fibrinolysis. Korean J. Intern. Med. 1992; 7: 81-6.
53. Landin K, Tengborn L, Smith U. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb. Haemost. 1994; 71: 783-7.
54. Nair CH, Azhar A, Wilson JD, Dhall DP. Studies on fibrin network structure in human plasma. Part II Clinical application: Diabetes and antidiabetic drugs. Thromb. Res. 1991; 64: 477-85.